Significant Update on ADR Ratio for Biodexa Pharmaceuticals
Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a forward-thinking clinical-stage biopharmaceutical company dedicated to developing solutions for unmet medical needs, has recently announced a significant change regarding its American Depositary Receipts (ADRs). This change, which will take effect soon, will adjust the current ratio from one ADR representing four hundred ordinary shares to a new ratio where one ADR represents ten thousand ordinary shares.
What You Need to Know About the ADR Ratio Change
This adjustment means that current ADR holders must surrender their existing ADRs to obtain one new ADR for every twenty-five old ADRs they possess. This process is designed to avoid issuing any fractional ADRs. If there are any resulting fractions, they will be sold, and the net proceeds will be distributed back to the respective holders. JP Morgan Chase Bank, N.A., will manage these exchanges efficiently.
Implications for Stakeholders
The effects of this Ratio Change can be seen as a one-for-twenty-five reverse ADR split. This step aims to help adjust the price of Biodexa's ADRs to meet the Nasdaq minimum bid price requirement of $1.00. However, the company acknowledges that they cannot guarantee that this change will definitely achieve this target.
Why the Change is Happening
This tactical decision to revise the ADR ratio is part of Biodexa’s broader strategy to strengthen its market presence and ensure compliance. By effectively managing their ADR structure, the company aims to stabilize and possibly increase investor interest, which is crucial for their ongoing operations and future funding prospects.
Message from the CEO
Stephen Stamp, the CEO and CFO of Biodexa Pharmaceuticals, remarked that this transition is anticipated to enhance the attractiveness of their ADRs, ultimately benefiting shareholders as they navigate the complexities of the biopharmaceutical landscape.
Company Contact Information
For investors and ADR holders seeking more information about this change or requiring assistance, they can get in touch directly with:
**Biodexa Pharmaceuticals PLC**
Tel: +44 (0)29 2048 0180
Website: www.biodexapharma.com
Frequently Asked Questions
What’s the main reason for the ADR ratio change?
The primary aim of changing the ADR ratio is to ensure Biodexa’s ADR prices comply with Nasdaq's minimum bid price requirement.
How will the exchange process work for current ADR holders?
Current ADR holders will need to surrender their old ADRs to receive new ADRs in an exchange process coordinated by JP Morgan Chase Bank, N.A.
When will the new ADR ratio take effect?
The new ADR ratio is expected to take effect shortly after this announcement.
Will the ordinary shares of Biodexa be impacted by this change?
No, the ordinary shares of Biodexa will not be affected by the Ratio Change.
Where can I find additional information about Biodexa Pharmaceuticals?
You can find more details on the Biodexa Pharmaceuticals website or contact the company directly using the provided phone number.
